Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PhaseBio Initiates Phase II Study for Coronavirus Patients

by Zacks Equity Research

PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

Why Is BioDelivery (BDSI) Down 0.4% Since Last Earnings Report?

by Zacks Equity Research

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

BioDelivery (BDSI) Beats on Q1 Earnings, Withdraws Guidance

by Zacks Equity Research

BioDelivery's (BDSI) strong Belubca sales drive the topline. Symproic further boosts revenues. Stock up.

BioDelivery Sciences International (BDSI) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

BioDelivery (BDSI) delivered earnings and revenue surprises of 400.00% and 15.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioDelivery (BDSI) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

BioDelivery (BDSI) beats earnings and sales expectations for the fourth quarter of 2019.

BioDelivery Sciences International (BDSI) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

BioDelivery (BDSI) delivered earnings and revenue surprises of 700.00% and 4.98%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

BioDelivery Sciences International (BDSI) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

BioDelivery (BDSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.

Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y

by Zacks Equity Research

Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.

Gilead's Mantle Cell Lymphoma Drug MAA Gets EMA Validation

by Zacks Equity Research

Gilead's (GILD) Marketing Authorization Application for KTE-X19 has been fully validated and is now under evaluation with the EMA.

Here's Why You Should Add BioDelivery Stock to Your Portfolio

by Zacks Equity Research

Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.

Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?

by Zacks Equity Research

Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.

What Makes BioDelivery (BDSI) a New Buy Stock

by Zacks Equity Research

BioDelivery (BDSI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Flexion's (FLXN) Stock Up on FDA Approval for Zilretta sNDA

by Zacks Equity Research

Flexion's (FLXN) sNDA for osteoarthritis drug, Zilretta, seeking removal of confusing limitation of use label, gets FDA approval.

Are You Looking for a Top Momentum Pick? Why BioDelivery Sciences International (BDSI) is a Great Choice

by Zacks Equity Research

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

BioDelivery (BDSI) Up 6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

What Makes BioDelivery Sciences International (BDSI) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does BioDelivery Sciences International (BDSI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zealand Initiates Second Late-Stage CHI Study on Dasiglucagon

by Zacks Equity Research

Zealand (ZEAL) announces initiation of the second phase III study to evaluate dasiglucagon in pediatric patients with congenital hyperinsulinism.

    Zacks.com featured highlights include: Sciences International, Air Industries, Hallmark Financial Services and Vector

    by Zacks Equity Research

    Zacks.com featured highlights include: Sciences International, Air Industries, Hallmark Financial Services and Vector

    Amarin's Vascepa MAA for Heart Risk Indication Accepted in EU

    by Zacks Equity Research

    The EMA validates Amarin's (AMRN) regulatory application seeking approval for Vascepa as a treatment to reduce risk of cardiovascular events.

    Nitish Marwah headshot

    5 Affordable Breakout Stocks for Stunning Returns

    by Nitish Marwah

    Selecting breakout stocks continues to be one of the most popular methods utilized by active investors.

    BioDelivery's Belbuca Sales & Symproic Addition Encouraging

    by Zacks Equity Research

    BioDelivery's (BDSI) efforts to increase preferred coverage for Belbuca and the acquisition of the rights to Symproic are likely to help continue its momentum.

    The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Jounce Therapeutics, BioDelivery Sciences International, Ironwood Pharmaceuticals, Osmotica Pharmaceuticals and Select Medical